Guggenheim Capital LLC Halozyme Therapeutics, Inc. Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 78,865 shares of HALO stock, worth $3.86 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

78,865

Previous 83,052 5.04%

Holding current value

$3.86 Million

Previous $4.35 Million 3.75%

% of portfolio

0.03%

Previous 0.03%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$51.3 - $64.42 $214,793 - $269,726	-4,187 Reduced 5.04%	78,865 $4.51 Million
Q2 2024 Aug 14, 2024	SELL	$37.81 - $52.4 $814,654 - $1.13 Million	-21,546 Reduced 20.6%	83,052 $4.35 Million
Q1 2024 May 14, 2024	BUY	$33.68 - $41.95 $1.22 Million - $1.52 Million	36,334 Added 53.23%	104,598 $4.26 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $130,581 - $164,989	-3,919 Reduced 5.43%	68,264 $2.52 Million
Q3 2023 Nov 14, 2023	SELL	$36.46 - $44.03 $108,286 - $130,769	-2,970 Reduced 3.95%	72,183 $2.76 Million
Q2 2023 Aug 11, 2023	SELL	$30.28 - $38.74 $173,837 - $222,406	-5,741 Reduced 7.1%	75,153 $2.71 Million
Q1 2023 May 10, 2023	BUY	$32.86 - $55.7 $72,061 - $122,150	2,193 Added 2.79%	80,894 $3.09 Million
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $429,002 - $636,542	10,709 Added 15.75%	78,701 $4.48 Million
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $381,215 - $512,311	-9,894 Reduced 12.7%	67,992 $2.69 Million
Q2 2022 Aug 15, 2022	SELL	$37.35 - $48.3 $339,847 - $439,481	-9,099 Reduced 10.46%	77,886 $3.43 Million
Q1 2022 May 16, 2022	BUY	$31.97 - $41.06 $233,157 - $299,450	7,293 Added 9.15%	86,985 $3.47 Million
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $398,131 - $509,864	-12,512 Reduced 13.57%	79,692 $3.21 Million
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $56,089 - $67,680	1,458 Added 1.61%	92,204 $3.75 Million
Q2 2021 Aug 13, 2021	BUY	$38.84 - $51.31 $123,550 - $163,217	3,181 Added 3.63%	90,746 $4.12 Million
Q1 2021 May 13, 2021	SELL	$39.51 - $51.45 $105,215 - $137,011	-2,663 Reduced 2.95%	87,565 $3.65 Million
Q4 2020 Feb 16, 2021	BUY	$25.81 - $43.62 $2.33 Million - $3.94 Million	90,228 New	90,228 $3.85 Million
Q2 2020 Aug 14, 2020	SELL	$16.25 - $26.81 $312,016 - $514,778	-19,201 Closed	0 $0
Q1 2020 Jun 02, 2020	BUY	$13.9 - $21.83 $266,893 - $419,157	19,201 New	19,201 $345,000
Q2 2018 Aug 14, 2018	SELL	$16.87 - $20.3 $2.7 Million - $3.25 Million	-160,173 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$17.06 - $21.2 $11,498 - $14,288	-674 Reduced 0.42%	160,173 $3.14 Million
Q4 2017 Feb 14, 2018	SELL	$16.75 - $20.8 $880,748 - $1.09 Million	-52,582 Reduced 24.64%	160,847 $3.26 Million
Q3 2017 Nov 14, 2017	BUY	$11.76 - $17.4 $2.51 Million - $3.71 Million	213,429	213,429 $3.71 Million

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.83B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Halozyme Therapeutics, Inc. Transaction History